keyword
MENU ▼
Read by QxMD icon Read
search

Marginal Zone Lymphoma

keyword
https://www.readbyqxmd.com/read/29340761/long-term-efficacy-and-toxicity-of-rituximab-plus-fludarabine-and-mitoxantrone-r-fm-for-gastric-marginal-zone-lymphoma-a-single-center-experience-and-literature-review
#1
Emanuele Cencini, Alberto Fabbri, Francesco Lauria, Monica Bocchia
There is no consensus about the best treatment option for patients with HP-negative gastric MALT lymphomas or persistent disease after HP eradication.We have investigated fludarabine and mitoxantrone with rituximab (R-FM) as first-line treatment. A cohort of 13 patients was analyzed. Induction treatment consisted of fludarabine (25 mg/m2 i.v. on days 2 to 4), mitoxantrone (10 mg/m2 i.v. on day 2), and rituximab (375 mg/m2 i.v. on day 1), for up to six cycles every 28 days. All patients achieved a complete remission, a median of four cycles was given...
January 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29331570/meningeal-marginal-zone-b-cell-lymphoma-the-meningioma-trap
#2
Alexandre Villeneuve, François Rubin, Pierre Bonfils
OBJECTIVE: To report a case of marginal zone MALT lymphoma of the temporal dura mater, initially mistaken for temporal meningioma. CASE REPORT: A 60-year-old immunocompetent woman, followed for more than 10 years for temporal meningioma causing vertigo and mixed hearing loss, presented with cervical lymphadenopathy, revealing marked progression of an intracranial lesion, leading to a diagnosis of marginal zone MALT lymphoma based on histological examination of a cervical lymph node...
January 10, 2018: European Annals of Otorhinolaryngology, Head and Neck Diseases
https://www.readbyqxmd.com/read/29325249/-clinicopathologic-features-of-primary-hepatic-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue-and-hepatic-pseudolymphoma
#3
C Liu, X Li, H Li, Q X Gong, Y Li, Z Wang, Z H Zhang
Objective: To study the clinicopathological features of primary hepatic extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) and hepatic pseudolymphoma, and to discuss their differential diagnosis, treatment and prognosis. Methods: Three primary hepatic MALT lymphomas and two hepatic pseudolymphomas collected from January 2012 to March 2017 in the First Affiliated Hospital of Nanjing Medical University were evaluated by HE and immunohistochemistry(IHC), in-situ hybridization and immunoglobulin (Ig) gene rearrangement detection, and the relevant literature reviewed...
January 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/29320898/did-i-miss-it-discovering-hidden-coexisting-hematological-neoplasms-a-single-institutional-review-of-100-collision-tumors
#4
Evan Himchak, Etan Marks, Yang Shi, Yanhua Wang
A collision tumor is defined as two histologically distinct tumor types identified at the same anatomic site. Hematolymphoid proliferative disorders (HLPDs), which coincide with non-hematological neoplasms, can mimic an immune response and can easily be overlooked as an immune reaction to a solid organ neoplasm, especially when low grade. In order to avoid a delay in the diagnosis of a HLPD during the workup for a non-hematological neoplasm, we identified a cohort of 100 cases with a HLPD diagnosis during the initial workup and treatment of a non-hematological neoplasm, or vice versa...
January 1, 2018: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29319640/orbital-extranodal-marginal-zone-lymphoma-following-radiotherapy-a-report-of-2-cases
#5
Zujaja Tauqeer, Frederick A Jakobiec, Suzanne K Freitag, Michael K Yoon, Natalie Wolkow
PURPOSE: To present 2 patients in whom orbital radiation preceded the development of periorbital extranodal marginal zone lymphoma by more than a decade and to investigate the likelihood of this representing irradiation-induced malignancy. METHODS: Retrospective chart review and histopathologic study with immunohistochemistry of 2 cases. RESULTS: The first patient was a 58-year-old woman who developed an orbital mass within the vicinity of the lateral rectus muscle 17 years after external beam proton radiation therapy for an inferotemporal choroidal melanoma...
January 9, 2018: Ophthalmic Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/29313941/image-gallery-metachronic-occurrence-of-primary-cutaneous-marginal-zone-b-cell-lymphoma-and-primary-cutaneous-rosai-dorfman-disease-in-the-same-patient
#6
A González-Quesada, J Bastida, J C Rivero-Vera, M A Piris-Pinilla, M A Limeres-González
No abstract text is available yet for this article.
December 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/29311729/marginal-zone-lymphoma-of-the-entire-gastrointestinal-tract
#7
Cameron Schauer, Robert Cunliffe
No abstract text is available yet for this article.
January 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29309299/comparison-of-myocyte-enhancer-factor-2b-versus-other-germinal-center-associated-antigens-in-the-differential-diagnosis-of-b-cell-non-hodgkin-lymphomas
#8
Erika M Moore, Steven H Swerdlow, Sarah E Gibson
Myocyte enhancer binding factor 2B (MEF2B) is a transcriptional activator of the BCL6 proto-oncogene in normal germinal center (GC) B-cells. Limited data exists concerning its expression in B-cell lymphomas, and comparison with other GC-associated antigens is lacking. Its role in the differential diagnosis of B-cell lymphomas, particularly in the distinction of follicular lymphoma (FL) versus marginal zone lymphoma (MZL), remains to be determined. We evaluated MEF2B expression, in comparison with additional GC markers, LIM domain-only transcription factor 2 (LMO2), and human GC-associated lymphoma (HGAL), in a variety of B-cell lymphomas, with particular emphasis on their utility in differentiating FL from MZL...
January 5, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29296886/constitutive-ras-signaling-and-ink4a-arf-inactivation-cooperate-during-the-development-of-b-all-in-mice
#9
Tomasz Sewastianik, Meng Jiang, Kumar Sukhdeo, Sanjay S Patel, Kathryn Roberts, Yue Kang, Ahmad Alduaij, Peter S Dennis, Brian Lawney, Ruiyang Liu, Zeyuan Song, Jessie Xiong, Yunyu Zhang, Madeleine E Lemieux, Geraldine S Pinkus, Jeremy N Rich, David M Weinstock, Charles G Mullighan, Norman E Sharpless, Ruben D Carrasco
Despite recent advances in treatment, human precursor B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging clinical entity. Recent genome-wide studies have uncovered frequent genetic alterations involving RAS pathway mutations and loss of the INK4A/ARF locus, suggesting their important role in the pathogenesis, relapse, and chemotherapy resistance of B-ALL. To better understand the oncogenic mechanisms by which these alterations might promote B-ALL and to develop an in vivo preclinical model of relapsed B-ALL, we engineered mouse strains with induced somatic KrasG12D pathway activation and/or loss of Ink4a/Arf during early stages of B-cell development...
November 28, 2017: Blood Advances
https://www.readbyqxmd.com/read/29296768/patient-derived-xenografts-of-low-grade-b-cell-lymphomas-demonstrate-roles-of-the-tumor-microenvironment
#10
W Richard Burack, Janice M Spence, John P Spence, Stephen A Spence, Philip J Rock, Gautam N Shenoy, Leonard D Shultz, Richard B Bankert, Steven H Bernstein
To discern features of non-Hodgkin lymphomas (NHL) that are autonomous from those that are shaped by the tumor environment (TE), we used patient-derived xenografts (PDX) to probe the effects on neoplastic cells of manipulating the TE. Properties of neoplastic cells that are often considered to be autonomous include their relative independence from stromal support, their relative survival and/or proliferation advantages compared with nonneoplastic cells, and their state of differentiation. Prior approaches to creation of PDX models likely select for neoplasms, which are the most capable of engraftment, potentially masking the effects of the TE...
July 11, 2017: Blood Advances
https://www.readbyqxmd.com/read/29288421/first-line-treatment-with-bendamustine-and-rituximab-in-patients-with-intermediate-high-risk-splenic-marginal-zone-lymphomas
#11
Roberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
Splenic marginal zone lymphomas (SMZLs) are rare indolent B cell neoplasms that affect the spleen, bone marrow, and blood. Although they have an indolent course in the majority of patients, who have a median survival of 8-10 years, ∼ 30% may experience a worse outcome. The prognostic criteria of progression are lymph node and extra-nodal involvement, high lymphocyte counts, anaemia, and thrombocytopenia. The treatment of SMZLs include a "wait and watch strategy", splenectomy, and alkylating agents ± rituximab...
December 29, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29286565/children-and-adolescents-with-marginal-zone-lymphoma-have-an-excellent-prognosis-with-limited-chemotherapy-or-a-watch-and-wait-strategy-after-complete-resection
#12
Leila Ronceray, Oussama Abla, Shlomit Barzilai-Birenboim, Simon Bomken, Alan Ks Chiang, Janez Jazbec, Edita Kabickova, Jelena Lazic, Auke Beishuizen, Karin Mellgren, Fumiko Tanaka, Marta Pillon, Christine Devalck, Marina Gouttenoire, Olga Makarova, Birgit Burkhardt, Andishe Attarbaschi
Data on management of pediatric marginal zone lymphoma (MZL) are scarce. This retrospective study assessed characteristics and outcome in 66 patients who were <18 years old. Forty-four (67%) had an extranodal MZL (EMZL), 21 (32%) a nodal MZL (NMZL), and one patient a splenic MZL. Thirty-three patients (50%) received a variable combination of adjuvant chemotherapy/immunotherapy/radiotherapy, while the remainder, including 20 of 21 with NMZL, entered an active observation period. Overall survival was excellent (98 ± 2%), although 11 patients relapsed (17%; NMZL, n = 1; EMZL, n = 10), seven after any therapy and four after complete resection only...
December 29, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29260925/effective-management-strategies-for-patients-with-marginal-zone-lymphoma
#13
Cecilia B Rosand, Kelly Valla, Christopher R Flowers, Jean L Koff
Marginal zone lymphoma (MZL) is an uncommon indolent lymphoma classified into subtypes based on primary site of involvement: splenic, nodal and extranodal. MZLs' relative rarity has largely precluded adoption of a standard management strategy. Here, we provide an overview of the epidemiology, clinical behavior and therapeutic approaches for each subtype. Biologic insights into lymphomagenesis have identified B-cell receptor signaling as a rational therapeutic target. Recent clinical data suggest that novel agents targeting this pathway, including the Bruton's tyrosine kinase inhibitor, ibrutinib, show significant promise in treatment of relapsed MZL...
December 20, 2017: Future Oncology
https://www.readbyqxmd.com/read/29260074/bilateral-orbital-marginal-zone-b-cell-lymphoma-of-the-mucosa-associated-lymphoid-tissue-in-a-patient-with-hepatitis-b-virus-infection
#14
Pei-Hsuan Lin, Yoshiyuki Kitaguchi, Jacqueline Mupas-Uy, Yasuhiro Takahashi, Hirohiko Kakizaki
Purpose: To report a case of marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the bilateral orbit with chronic hepatitis B virus (HBV) infection. Observations: A 72-year-old man with chronic HBV infection presented with a bilateral proptosis with slight restriction of ocular motility for 9 months. Computed tomographic images showed well-defined, isodense masses in the bilateral superolateral orbit. Magnetic resonance images showed isointense on T1-and hyperintense on T2-weighted images, with bilateral involvements of the lateral rectus muscles reaching the superior orbital fissures...
September 2017: American Journal of Ophthalmology Case Reports
https://www.readbyqxmd.com/read/29246929/sarcoidosis-lymphoma-syndrome-a-diagnostic-dilemma
#15
Assad Oskuei, Lisa Hicks, Hasan Ghaffar, Victor Hoffstein
Sarcoidosis and lymphoma are generally thought of as being two mutually exclusive diseases that need to be considered in the differential diagnosis of patients with hilar/mediastianal lymphadenopathy. However, there are rare patients in whom both of these diseases coexist. These patients constitute a diagnostic challenge because their presentation (ie, clinical symptoms, imaging abnormalities and even pathology) may all be atypical when each individual disease is considered separately. In this report, we describe a patient who presented with such atypical features and was eventually diagnosed as having both sarcoidosis and a B-cell lymphoma with features of splenic marginal zone lymphoma (SMZL) simultaneously...
December 14, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29239080/hcv-positive-lymphoma-after-sustained-virological-response-with-direct-acting-antiviral-agents-the-game-is-not-over-after-hcv-eradication
#16
E Rodríguez de Santiago, K Velázquez Kennedy, M García González, F Gea Rodríguez, L Téllez Villajos, E Tavío Hernández, A Albillos Martínez
We read with interest the study published by Schiavinato A. et al. entitled: " Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents"[1]. There is extensive data supporting the association between hepatitis C virus (HCV) and B-cell non-Hodgkin lymphoma (B-cell NHL), especially with marginal zone and diffuse large B-cell NHL subtypes. Antiviral treatment with Interferon-based regimens has been shown to improve prognosis and can be curative in some cases of indolent lymphoma...
December 14, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29228725/distinct-clinical-characteristics-draw-a-new-prognostic-model-for-splenic-marginal-zone-lymphoma-in-hbv-high-prevalent-region
#17
Shuhua Yi, Yuting Yan, Wenjie Xiong, Rui Lv, Zhen Yu, Wei Liu, Enbin Liu, Heng Li, Huimin Liu, Zengjun Li, Gang An, Yan Xu, Kun Ru, Dehui Zou, Lugui Qiu
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell neoplasm with hepatitis virus supposed to involve in the pathogenesis. The characteristics of SMZL derived from Caucasia population and high hepatitis C virus (HCV) infection region have been widely investigated, but few was reported in the Eastern population with HBV prevalent region. We analyzed the clinical characteristics, cytogenetic aberrations and prognostic factors in 160 SMZL patients from China. 25 patients (16%) were HBsAg-positive and 54 (34%) patients with resolved HBV infection...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228090/epstein-barr-virus-positive-extranodal-marginal-zone-lymphoma-of-bronchial-associated-lymphoid-tissue-in-the-posttransplant-setting-an-immunodeficiency-related-posttransplant-lymphoproliferative-disorder
#18
Daniel P Cassidy, Francisco Vega, Jennifer R Chapman
Objectives: Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of hematolymphoid proliferations arising in the context of chronic immunosuppression. The common and indolent B-cell lymphomas, including extranodal marginal zone lymphomas (ENMZLs) of mucosa-associated lymphoid tissue (MALT), are excluded from the category of PTLD in the current World Health Organization classification. Methods: We report a case of Epstein-Barr virus (EBV)-positive bronchial-associated lymphoid tissue (BALT) lymphoma involving the lungs of a transplant patient...
December 7, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29225710/novel-developments-in-the-pathogenesis-and-diagnosis-of-extranodal-marginal-zone-lymphoma
#19
REVIEW
Max I Schreuder, Michiel van den Brand, Konnie M Hebeda, Patricia J T A Groenen, J Han van Krieken, Blanca Scheijen
Extranodal marginal zone lymphoma (EMZL), mostly represented by mucosa-associated lymphoid tissue (MALT) type, also referred to as MALT lymphoma, is a clinically heterogeneous entity within the group of low-grade B cell lymphomas that arises in a wide range of different extranodal sites, including the stomach, lung, ocular adnexa, and skin. It represents the third most common non-Hodgkin lymphoma in the Western world, and the median age of occurrence is around 60 years. One characteristic aspect in a subset of EMZL detectable in about 25% of the cases is the presence of specific chromosomal translocations involving the genes MALT1 and BCL10, which lead to activation of the NF-κB signaling pathway...
December 2017: Journal of Hematopathology
https://www.readbyqxmd.com/read/29222281/improved-biological-insight-and-influence-on-management-in-indolent-lymphoma-talk-3-update-on-nodal-and-splenic-marginal-zone-lymphoma
#20
REVIEW
Catherine Thieblemont
Splenic marginal zone lymphoma (SMZL) and nodal marginal zone lymphoma (NMZL) are rare indolent chronic B-cell lymphomas. Prognosis is typically good with median survival around 10-15 years. Management is generally based on the presence of symptoms or high tumor burden. There are no standard treatments for these 2 entities, and therapeutic strategies are rapidly evolving. Clinical developments for these 2 entities are oriented by genomic studies, with largely overlapping mutational profiles involving the NOTCH, B-cell receptor (BcR) and nuclear factor κB (NF-κB) signaling, chromatin remodeling, and the cytoskeleton...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
keyword
keyword
15670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"